Technical Analysis for VAXX - Vaxxinity, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bullish Engulfing | Bullish | -10.00% | |
| Narrow Range Bar | Range Contraction | -10.00% | |
| Wide Bands | Range Expansion | -10.00% | |
| Oversold Stochastic | Weakness | -10.00% | |
| New 52 Week Closing Low | Bearish | 12.50% | |
| Narrow Range Bar | Range Contraction | 12.50% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 10 hours ago |
| Down 5% | about 14 hours ago |
| Down 3% | about 14 hours ago |
| Down 2 % | about 14 hours ago |
| Down 1% | about 14 hours ago |
Get a Trading Sidekick!
- Earnings date: 06/19/2024
Vaxxinity, Inc. Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Alzheimer's Disease Parkinson's Disease Neurological Disorders Dementia Amyloidosis Neurodegenerative Disorders Lewy Body Dementia Migraine Multiple System Atrophy Neuropathology Pcsk9
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.1 |
| 52 Week Low | 0.0453 |
| Average Volume | 2,614,185 |
| 200-Day Moving Average | 1.00 |
| 50-Day Moving Average | 0.46 |
| 20-Day Moving Average | 0.16 |
| 10-Day Moving Average | 0.09 |
| Average True Range | 0.05 |
| RSI (14) | 23.08 |
| ADX | 48.87 |
| +DI | 11.38 |
| -DI | 35.86 |
| Chandelier Exit (Long, 3 ATRs) | 0.36 |
| Chandelier Exit (Short, 3 ATRs) | 0.19 |
| Upper Bollinger Bands | 0.39 |
| Lower Bollinger Band | -0.08 |
| Percent B (%b) | 0.28 |
| BandWidth | 298.33 |
| MACD Line | -0.12 |
| MACD Signal Line | -0.12 |
| MACD Histogram | 0.008 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.07 | ||||
| Resistance 3 (R3) | 0.07 | 0.07 | 0.07 | ||
| Resistance 2 (R2) | 0.07 | 0.06 | 0.07 | 0.07 | |
| Resistance 1 (R1) | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 |
| Pivot Point | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
| Support 1 (S1) | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 |
| Support 2 (S2) | 0.05 | 0.05 | 0.04 | 0.04 | |
| Support 3 (S3) | 0.04 | 0.05 | 0.04 | ||
| Support 4 (S4) | 0.04 |
